

REXAM

Lilly

Press Release
16 June 2008

1/12

Rexam and Lilly laboratories, partners in the production of a new insulin injection pen

Press contacts

Rexam Pharma:

Laurence Quesdeville, communication department,
+33 (0)1 58 47 56 82, laurence.quesdeville@rexam.com

Lilly, Fergersheim site:

•Marie-Antoinette Klein, communication department,
+33 (0)3 90 64 40 00, mak@lilly.com

•laCompagnie: Patrice Heintz or Sabrina Curo, s.curto@lacompanie.org

The logo for REXAM, with 'REX' in black and 'AM' in blue.The logo for Lilly, written in a red cursive script.A large, abstract orange shape on the right side of the page, containing text.

Contents
16 June 2008

2/12

Rexam and Lilly laboratories, partners in the production of a new insulin injection pen

Contents

- I. News: Rexam and Lilly laboratories, partners in the production of a new insulin injection pen.
- II. Company info: Rexam Plc
- III. Company info: Rexam Pharma
- IV. Company info: The Eli Lilly and Company group. The Fegersheim (Strasbourg) production site
- V. Company info: Eli Lilly and Company – key figures
- VI. Market info: Diabetes, a disease of pandemic proportions
- VII. Appendices: photographs

Summary

Rexam, the world specialist in packaging, will be the European supplier for the Eli Lilly and Company group, of sub-sets of their new insulin injection pen. The production will be carried out by Rexam Pharma at its La Verpillière plant in Isère, where the inauguration ceremony of the future construction site of an extension takes place today, 16 June 2008. The 3,800 m² of this building will be set aside exclusively for manufacturing this product. The result of several years of collaboration between Rexam Pharma and the Eli Lilly and Company group, the agreement is expected to generate the creation of around fifty jobs at La Verpillière in the long term and its first industrial phase is scheduled for 2009.

A large, abstract grey shape on the bottom left side of the page.

<http://www.rexam.com/pharma>

<http://www.lilly.fr>

The logo for REXAM, with 'REXAM' in a bold, blue, sans-serif font.The logo for Lilly, written in a red, cursive script font.A large, abstract orange shape on the right side of the page, resembling a stylized 'S' or a drop. It contains text and a page number.

Press Release
16 June 2008

3/12

Rexam and Lilly laboratories, partners in the production of a new insulin injection pen.

Rexam, the world specialist in packaging, will be the European supplier for the Eli Lilly and Company group of the sub-sets of their new insulin injection pen. This production will be carried out by Rexam Pharma at its La Verpillière plant in Isère, where the inauguration ceremony of the future construction site of an extension takes place on 16 June 2008. The 3,800 m² of this building will be reserved exclusively for the production of this product. The result of several years' collaboration between Rexam Pharma and the Eli Lilly and Company group, the agreement is expected to generate the creation of around fifty jobs at La Verpillière in the long run and its first industrial phase is scheduled for 2009.

Composed of over a dozen plastic parts and a metal spring, this new insulin injection pen for the treatment of diabetes is broken down into two sub-sets: one sub-set which constitutes the dose selection mechanism, and another which forms a protective cap. The glass cartridge filled with insulin which is inserted in the pen is produced by the Eli Lilly and Company group at their Fegersheim site near Strasbourg. It is at this site that the assembly of the two sub-sets around the cartridge of medicine is also carried out, during the final assembly process of the pen.

At Rexam's La Verpillière site, the components of the injection pen will be manufactured by a fleet of robotic machines, dedicated exclusively to this production: injection presses, marking machines, assembly line with ultrasound welding, sticking and packaging technology. Each phase will be controlled by a camera viewing system. Designed to be produced by multi-imprint molds on electric injection presses, the plastic parts will be in a material chosen specifically by the Eli Lilly and Company group in view of the end use of the device. Prior to marketable production, a validation of the equipment according to strict protocols should offer diabetic patients who use this pen perfect reproducibility of the injected doses.

.../...

REXAM



Press Release
16 June 2008

4/12

.../...

It was at the time of the acquisition of the Plastic Omnium Medical division in 2004 that the La Verpillière plant joined the Rexam group. It specialises in drug administration systems, such as inhalers for asthma and injection devices, which enable the patient to self-administer their medicines. The plant therefore manufactures according to Good Manufacturing Practice (GMP), in compliance with pharmaceutical industry requirements. This GMP applies to both the actual medicine and its container. Thus 2,400 m² out of the extension's 3,800 m² will be cleanrooms complying with standard ISO8.

Meanwhile, the Eli Lilly and Company group's most important production site situated at Fegersheim is transforming the existing 600 m² and investing around 35 million euros in new production methods, the first of which will be delivered in the second half of 2008. The new pen which will come from this plant is to be marketed worldwide.

In 2005, after Rexam's acquisition of Precise Technology USA, a relationship of trust was established between Rexam Pharma at La Verpillière and Lilly Laboratories' production site of injectable medicines at Fegersheim.

Rexam has demonstrated its capacity to manage a large scale industrial project. Lilly, for its part, is bolstering its supplier portfolio for its plastic parts, and entrusting the production of the parts of its new pen to a plant in Europe. At both Rexam and Lilly, project teams and groups of specialised sectors are making this long-term cooperation possible. The partnership between the world No. 2 in consumer packaging, listed on the London Stock Exchange, and the world No. 10 of the pharmacy sector, are expected to create around fifty specialised jobs in France, at La Verpillière.

Lilly and Rexam, each managing their production processes in totally different but complementary core sectors, are together creating real value added in France, for the entire benefit of diabetic patients throughout the world.

Contact us:

Rexam Pharma:

•Laurence Quesdeville, +33 (0)1 58 47 56 82, laurence.quesdeville@rexam.com

Lilly, Fegersheim site:

•Marie-Antoinette Klein, +33 (0)3 90 64 40 00, mak@lilly.com

•laCompagnie: Patrice Heintz ou Sabrina Curo, s.curto@lacompanie.org

The logo for REXAM, with 'REX' in black and 'AM' in blue.The Lilly logo in a red, cursive script.A large, abstract orange shape on the right side of the slide, containing text and a page number.

Company info: Rexam
16 June 2008

5/12

Company info: Rexam Plc

Rexam is the number 2 worldwide in global consumer packaging. Rexam is a leading global consumer packaging company. It is the largest beverage can maker in the world and a global leader in rigid plastic packaging. Our vision is to be the leading global consumer packaging company.

We are business partners to some of the world's most famous and successful consumer brands as well as young, entrepreneurial start-ups. We offer a broad range of packaging services and solutions for different industries, using different materials and technologies.

Three things characterise us – leadership in our industry, our commitment to innovation and our passion to deliver exceptional value.

Rexam's sales from ongoing operations are approximately £3.6 billion. We employ some 23,500 people in more than 20 countries and are a member of the FTSE 100. Rexam's ordinary shares are listed with the UK Listing Authority and trade on the London Stock Exchange under the symbol REX.

With the acquisition of O-I Plastics, Rexam further boosted its leading position in health packaging, drug distribution systems and medical devices.

For further information on Rexam, visit www.rexam.com



The logo for REXAM, with 'REXAM' in a bold, blue, sans-serif font.The Lilly logo, featuring the word 'Lilly' in a red, cursive script font.A large, abstract orange shape on the right side of the page, containing text and a page number.

Company info: Rexam
16 June 2008

6/12

Company info: Rexam Pharma

Rexam Pharma, a division of Rexam Plastic Packaging, specialises in rigid plastic packaging, drug delivery systems and medical devices for the pharmaceutical and medical industries and the biotechnologies.

Using in-depth expertise in plastic injection and high-speed automated assembly, Rexam Pharma offers the widest product range on the market: drug delivery systems, medical devices, metering pumps and valves, plastic primary packaging and diagnostic disposables.

Rexam Pharma also has comprehensive resources which enable it to develop innovative packaging solutions for its clients. From the conception phase to the final design of the product, development of the prototype and industrialisation, Rexam Pharma supplies a solution resolutely targeting patients with a complex problem.

From the quality point of view, Rexam Pharma manufactures according to the GMP and ISO 9001/2000 standards at each of its plants. It strictly adheres to ISO certification 13485:2003 relating to medical devices and offers in-depth experience of DMFs and clean-environment production, up to class ISO 5, class A-GMP.

A worldwide industrial and commercial establishment and technologies geared to innovation enable Rexam Pharma to supply ever more value added to patients.

For further information: www.rexam.com/pharma

A large, abstract grey shape at the bottom left of the page, resembling a stylized profile or a decorative element.

The logo for REXAM, with 'REX' in black and 'AM' in blue.The Lilly logo in a red, cursive script.A large, abstract orange shape on the right side of the slide, containing text and a page number.

Company info: Rexam
16 June 2008

7/12

Company info: Rexam Pharma La Verpillière SAS

The La Verpillière site (Isère, France) joined Rexam Pharma in 2004 at the time of the Rexam group's acquisition of Plastic Omnium Medical.

This site specialises in drug delivery systems such as asthma inhalers and injection devices.

Currently offering a cleanroom of over 5,000 m², this plant complies with the Good Manufacturing Practices in accordance with the requirements applied by pharmaceutical companies both for the actual medicinal product and its container.

The plant won the Rexam Lean Gold Award in 2007. A system which supports identification, sharing, implementation and follow-up of best industrial practices for continuous improvement.

The La Verpillière site houses Rexam Pharma's European technology centre, created with a view to providing its clients with all necessary support in developing their products.



The logo for REXAM, with 'REX' in black and 'AM' in blue.The Lilly logo in a red, cursive script.A large, abstract orange shape on the right side of the slide, containing text and a page number.

Company info: Eli Lilly
and Company
16 June 2008

8/12

Company info: the Eli Lilly and Company group The Fegersheim (Strasbourg) production site

The Fegersheim (Bas Rhin) site is the Lilly group's biggest industrial production site in the world. Built in 1967, situated in Alsace, near Strasbourg, it benefits from the highest technology and acts as a front-runner in multiple technical fields. It is the only site of the group to produce disposable injection pens and medicines in cartridges: insulin, growth hormone and parathyroid hormone. These products are biogenetic drugs, developed on the basis of recombination techniques. Fegersheim also manufactures Lilly's anti-cancer treatments.

At the heart of Lilly's innovation, the Fegersheim site makes wide use of Alsace's technical, university and scientific potential: 45% of employees have followed higher education, of whom 145 engineers, 80 doctors of pharmacy and 40 with a doctoral degree. It also has a team which will manage the interface between R&D and production, to optimise technology transfers.

Lilly invested more than 380 million euros in Fegersheim between 1992 and 2002 and 260 million are being dedicated to the development of the site between 2003 and 2009. The work involves, besides the refurbishment of a production building, the doubling of storage capacity and an increase in production capacity. The site, which tripled its workforce between 1993 and 2004, now has 1,800 collaborators.

For further information: www.lilly.fr



The logo for REXAM, with 'REX' in black and 'AM' in blue.The logo for Eli Lilly, written in a red cursive script.A large, abstract orange shape on the right side of the slide, containing text and a page number.

Company info: Eli Lilly
and company
16 June 2008


9/12

Company info: Eli Lilly and Company – key figures

Eli Lilly and Company

- Founded in 1876 and established in Indianapolis (Indiana, United States).
- 10th largest pharmaceutical laboratory in the world.
- Turnover of 18.7 billion dollars in 2007
- Research and development: 3.5 billion dollars, i.e. 18.7% of net sales
- Net profit: 2.9 billion dollars
- Established in 143 countries around the world.
- 40,600 collaborators around the world.
- Areas of activity:
 - Neuroscience
 - Endocrinology
 - Oncology
 - Intensive care
 - Anti-infection
 - Women's health
 - Urology
 - Animal health

Lilly France

- Created in 1962. The head office is based at Suresnes (Hauts-de-Seine).
 - 14th largest French pharmaceutical laboratory.
 - 4th largest subsidiary of the Group after the United States, Japan and Germany.
 - Turnover of 2.12 billion euros in 2007, of which 1.62 billion euros in exports, generated by the Fegersheim site.
 - 2,830 collaborators in total: Suresnes site, sales force in France and Fegersheim production site.
- 
- A large, abstract grey shape at the bottom left of the slide.

REXAM

Lilly

Market info
16 June 2008

10/12

Diabetes, a disease of pandemic proportions

There are an estimated 246 million diabetic patients in the world. More than 53 million people are diagnosed as such in Europe and the incidence of the disease is increasing constantly: 64 million Europeans are expected to be suffering from the disorder by 2025.

In France, there were 2,653,000 patients diagnosed as diabetic in 2003 (in addition to an estimated 1 to 1.5 million undiagnosed diabetics), i.e. 3.5% of the French population. By 2025 around 3,285,300 people are expected to be diagnosed as diabetic.

Poorly controlled diabetes costs the healthcare system 3.5 times more than efficiently controlled diabetes. Around 5% of Europe's health budget is dedicated to diabetes. The average cost of diabetes in Europe, estimated at €2,834 per patient per year, is significantly higher in France and Germany.



REXAM

Lilly

Appendix 1
16 June 2008

11/12

Available photographs

Photos: Félix Poirier – Lilly Photo library – June 2006



Cartridge filling2.jpg



Cartridge filling.jpg



Insulin cartridges.jpg



Insulin cartridge production.jpg



Pharmaceutical packaging (2).jpg



Pharmaceutical packaging (3).jpg



Insulin pen assembly.jpg



Aerial photograph. 2.jpg



Aerial photograph.jpg

REXAM

Lilly

Appendix 2
16 June 2008

12/12

Available photographs

Rexam photo library – June 2006



Rexam Pharma La Verpillière1.jpg



Rexam Pharma La Verpillière2.bmp



Rexam Pharma La Verpillière3.jpg



Rexam Pharma La Verpillière4.jpg



Rexam Pharma La Verpillière5.jpg